Christophe Bourdon

Christophe Bourdon is the current CEO of Leo Pharma. Christophe has also served as the Chief Executive Officer of Orphazyme A/S, Senior Vice President EMEAC at Alexion Pharmaceuticals, Inc., and Senior Vice President, General Manager, U.S. Oncology Business at Amgen.

Bourdon began their career in the French Civil Service before joining EADS in Japan as a financial controller. Christophe then moved to Sanofi, where they spent 11 years in various positions, including General Manager of Norway and Financial Controller of Japan. In 2005, they left Sanofi to join Stallergenes as Corporate Marketing Director.

Bourdon joined Amgen in 2007 as Vice President & General Manager of Germany. Christophe was promoted to Senior Vice President, General Manager, U.S. Oncology Business in 2018 and held this position until 2021 when they left Amgen to become the CEO of Orphazyme A/S. Christophe held this position for one year before returning to Amgen as the CEO of Leo Pharma.

Christophe Bourdon has a Master Business Administration from IMD and a Business Degree from ISG Institut Supérieur de Gestion.

Some direct reports include Philip Eickhoff - EVP & Chief Financial Officer, Jörg Möller - EVP, and Guillaume Clément - EVP, Region Europe.